Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis c patients treated with first generation protease inhibitor triple therapy: A preliminary analysis

Digestive Diseases and Sciences

Volumn 58, Issue 11, 2013, Pages 3348-3358

  Juneja, Manie ^a   Euliano, Rebekah ^a   Satoskar, Rohit ^a   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Boceprevir; Charlson comorbid index; Hepatitis C; Polypharmacy; Telaprevir

Indexed keywords

BOCEPREVIR; CYTOCHROME P450 3A4 INHIBITOR; PROTEINASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGED; ANEMIA; ARTICLE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DROWSINESS; DYSGEUSIA; FATIGUE; FEMALE; HAIR LOSS; HEPATITIS C; HUMAN; HYPOTHYROIDISM; INTERMETHOD COMPARISON; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; POLYPHARMACY; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; VOMITING;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG INTERACTIONS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYPHARMACY; PROLINE; RETROSPECTIVE STUDIES; RIBAVIRIN; VIRAL LOAD;

EID: 84889601451     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2812-9     Document Type: Article

References (31)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
2. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.
3. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292-1303.
4. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-1838.
5. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839-1850.
6. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology. 2010;51:388-397.
7. Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34:297-305.
8. Mir HM, Stepanova M, Afendy M, Kugelmas M, Younossi ZM. African Americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol. 2012;46:e62-e65.
9. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425-433.
10. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97-103.
11. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55:69-75.
12. Hu CC, Lin CL, Kuo YL, et al. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther. 2013;37:81-90.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
14. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
15. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3:383-389.
16. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867-2878.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
18. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079; discussion 1081-1090.
19. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55:1620-1628.
20. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-1444.
21. Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol. 2010;44:140-145.
22. Srivastava S, Bertagnolli M, Lewis JH. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naive patients in a university liver clinic. J Natl Med Assoc. 2005;97:1703-1707.
23. Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-Naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:344-350. e342.
24. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-129 e118.
25. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47:1884-1893.
26. Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67:507-519.
27. Berenbeim DM. Polypharmacy: overdosing on good intentions. Managed Care Q. 2002;10:1-5.
28. Baandrup L, Sorensen J, Lublin H, Nordentoft M, Glenthoj B. Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. Eur J Health Econ. 2012;13:355-363.
29. Fink A, Siu AL, Brook RH, Park RE, Solomon DH. Assuring the quality of health care for older persons. An expert panel's priorities. JAMA. 1987;258:1905-1908.
30. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006;124:491.
31. Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009;338:a2752.